Market Spotlight: Uterine Cancer
Market Spotlight: Uterine Cancer
$1,318.00
This Market Spotlight report covers the uterine cancer market, comprising key pipeline drugs, clinical trials, patent information, a 10-year disease incidence forecast, and licensing and acquisition deals.
Author: Informa Pharma Intelligence
Publisher: Datamonitor Healthcare
- Description
- Contents
This Market Spotlight report covers the uterine cancer market, comprising key pipeline drugs, clinical trials, patent information, a 10-year disease incidence forecast, recent events and analyst opinion, key upcoming events, probability of success, and licensing and acquisition deals.
Key Takeaways
- Datamonitor Healthcare estimates that in 2017, there were 377,900 incident cases of uterine cancer in females aged 15 years and over worldwide, and expects that number to increase to 413,600 incident cases by 2026.
- In the same year, there were an estimated 1.3 million five-year prevalent cases of uterine cancer worldwide, which is expected to increase slightly to 1.4 million cases by 2026.
- The majority of industry-sponsored drugs in active clinical development for uterine cancer are in Phase II, with three drugs in Phase III.
- Therapies in active clinical development for uterine cancer focus on a wide variety of targets. The majority of pipeline drugs are administered orally, with the remainder being tested in intravenous formulations.
- The only high-impact upcoming event for drugs in the uterine cancer space is topline Phase II trial results for XBIO-101. The overall likelihood of approval of a Phase I solid tumors asset is 5.6%, and the average probability a drug advances from Phase III is 40%. Drugs, on average, take 9.5 years from Phase I to approval, compared to 9.3 years in the overall oncology space.
- There have been nine licensing and asset acquisition deals involving endometrial cancer drugs during 2014–19. The $1,657m collaboration and exclusive license agreement signed in 2014 between AnaptysBio and Tesaro, pursuant to which Tesaro was granted exclusive rights to antibody programs targeting PD-1, TIM-3, and LAG-3, including monospecific and dual reactive antibody drug candidates, was the largest deal.
- The distribution of clinical trials across Phase I–IV indicates that the vast majority of trials for uterine neoplasms have been in the early and mid-phases of development, with 95% of trials in Phase I–II, and only 5% in Phase III–IV.
- The US has a substantial lead in the number of uterine neoplasms clinical trials globally, while Spain and the UK lead the major EU markets.
- Sanofi has the highest number of completed clinical trials for uterine neoplasms, with six trials.
- AstraZeneca, Eli Lilly, and Sanofi lead industry sponsors with the highest number of overall clinical trials for uterine neoplasms
CONTENTS
6 OVERVIEW
7 KEY TAKEAWAYS
8 DISEASE BACKGROUND
9 TREATMENT
9 Surgery
9 Radiation therapy
9 Chemotherapy
10 Hormone therapy
10 Palliative care
11 EPIDEMIOLOGY
15 PIPELINE DRUGS
22 RECENT EVENTS AND ANALYST OPINION
22 MGA012 for Uterine Cancer (July 2, 2019)
23 Sacituzumab Govitecan for Uterine Cancer (April 29, 2019)
23 TAK-117 for Uterine Cancer (March 20, 2019)
24 Dostarlimab for Uterine Cancer (March 19, 2019)
26 DKN-01 for Uterine Cancer (March 18, 2019)
27 Dostarlimab for Uterine Cancer (October 20, 2018)
29 Keytruda for Uterine Cancer (June 3, 2018)
30 Multiple Drugs for Uterine Cancer (March 7, 2018)
32 KEY UPCOMING EVENTS
33 KEY REGULATORY EVENTS
33 Tesaro’s On The Right Path With Anti-PD-1 Dostarlimab In Endometrial Cancer
33 Keytruda/Lenvima Gets Breakthrough Designation With Basket Trial
34 PROBABILITY OF SUCCESS
35 LICENSING AND ASSET ACQUISITION DEALS
35 Deals Shaping The Medical Industry, August 2019
36 PARENT PATENTS
37 CLINICAL TRIAL LANDSCAPE
39 Sponsors by status
40 Sponsors by phase
41 BIBLIOGRAPHY
42 APPENDIX
LIST OF FIGURES
13 Figure 1: Trends in incident cases of uterine cancer, 2017–26
15 Figure 2: Overview of pipeline drugs for uterine cancer in the US
16 Figure 3: Pipeline drugs for uterine cancer, by company
16 Figure 4: Pipeline drugs for uterine cancer, by drug type
16 Figure 5: Pipeline drugs for uterine cancer, by classification
26 Figure 6: Dostarlimab for Uterine Cancer (March 19, 2019): Phase I – GARNET
27 Figure 7: DKN-01 for Uterine Cancer (March 18, 2019): Phase II – Gynecologic Malignancies (P204)
29 Figure 8: Dostarlimab for Uterine Cancer (October 20, 2018): Phase I – GARNET
30 Figure 9: Keytruda for Uterine Cancer (June 3, 2018): Phase I/II – KEYNOTE-146 (w/Lenvima)
32 Figure 10: Key upcoming events in uterine cancer
34 Figure 11: Probability of success in the uterine cancer pipeline
35 Figure 12: Licensing and asset acquisition deals in uterine cancer, 2014–19
36 Figure 13: Parent patents in uterine cancer
37 Figure 14: Clinical trials in uterine cancer
38 Figure 15: Top 10 drugs for clinical trials in uterine cancer
38 Figure 16: Top 10 companies for clinical trials in uterine cancer
39 Figure 17: Trial locations in uterine cancer
40 Figure 18: Uterine cancer trials status
40 Figure 19: Uterine cancer trials sponsors by phase
LIST OF TABLES
12 Table 1: Incident cases of uterine cancer, 2017–26
14 Table 2: Five-year prevalent cases of uterine cancer, 2017–26
18 Table 3: Pipeline drugs for uterine cancer in the US
22 Table 4: MGA012 for Uterine Cancer (July 2, 2019)
23 Table 5: Sacituzumab Govitecan for Uterine Cancer (April 29, 2019)
24 Table 6: TAK-117 for Uterine Cancer (March 20, 2019)
25 Table 7: Dostarlimab for Uterine Cancer (March 19, 2019)
26 Table 8: DKN-01 for Uterine Cancer (March 18, 2019)
28 Table 9: Dostarlimab for Uterine Cancer (October 20, 2018)
29 Table 10: Keytruda for Uterine Cancer (June 3, 2018)
31 Table 11: Multiple Drugs for Uterine Cancer (March 7, 2018)
© Informa UK Ltd. This document is a licensed product and is not to be reproduced or redistributed
Do you have a subscription to Datamonitor Healthcare, Biomedtracker or Meddevicetracker? You may already have access to these reports, contact your account manager or email pharma@informabi.com for further help or assistance.
Sign up to the